Jupiter Neurosciences, Inc. JUNS 深 沪
已收盘 05-22 16:00:00 美东时间
0.2378
-0.033
-12.19%
华盛通- 最 高0.2572
- 今 开0.2549
- 成交量 844.57万股
- 最 低 0.23
- 昨 收 0.2708
- 总市值 1.03万
- 52周最高 3.33
- 市盈率 静 --
- 换手率 19449.23%
- 52周最低 0.1721
- 委 比 -34.36%
- 总股本 4.34万
- 历史最高 19.51
- 量 比 0.14
- 振 幅 10.04%
- 历史最低 0.1721
- 每 手 1
- 风险率 0.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jupiter Neurosciences Announces Registered Direct Equity Offering
Jupiter Neurosciences, Inc. ( ($JUNS) ) has provided an update. On May 20, 2026...
05-21 23:26
Why e.l.f. Beauty Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Shares of elf Beauty Inc (NYSE: ELF) rose sharply in pre-market trading after beating analyst expectations with fourth-quarter earnings of 32 cents per share and revenue of $449.29 million, up 35%. Other pre-market gainers include WHLR, ATPC, LIMN, JUNS, ILLR, NCPL, VIDA, WNW, and APLD. The biggest losers are WGRX, MMA, IPW, and CAPS.
05-21 17:21
Jupiter Neurosciences Pursues MDMA Asset Licensing Deal
Jupiter Neurosciences, Inc. ( ($JUNS) ) has provided an announcement. On May 19...
05-20 22:17
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 147.2% to ...
05-20 20:06
Jupiter Neurosciences To Acquire U.S. Licensing Rights To ALA-002 From Pharmala Biotech For $3.33M, Comprising $1.5M In Cash And $1.83M Of JUNS Stock
The shares will be subject to a 120-day Lock-up period. The term sheet also provides that additional development milestone payments and single digit royalties will be paid as the product is developed, approved and
05-20 19:49
Jupiter Neurosciences agrees to pay $3.33 million for exclusive US rights to PharmAla’s ALA-002
Jupiter Neurosciences agrees to pay $3.33 million for exclusive US rights to PharmAla’s ALA-002 Jupiter Neurosciences entered a term sheet to acquire exclusive, perpetual U.S. licensing rights to PharmAla Biotech’s ALA-002, a next-generation MDMA drug candidate. The deal values the upfront considera
05-20 19:38
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Jupiter Neurosciences, Inc. announced a registered direct offering of 7,142,858 common shares, raising approximately $2.0 million. D. Boral Capital LLC is the exclusive placement agent, with closing expected on May 21, 2026. The offering is under an effective SEC registration statement. The company, focused on CNS disorders and neuroinflammation, has a lead program in Phase IIa for Parkinson's disease and commercializes a longevity supplement. It...
05-20 18:38
Jupiter Neurosciences Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $18.652K Miss $225.000K Estimate
Jupiter Neurosciences (NASDAQ:JUNS) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. This is a 20 percent decrease over losses of $(0.05) per share from
05-15 05:10
Jupiter Neurosciences to Present at Emerging Growth Conference on April 2
Jupiter Neurosciences, Inc. has been invited to present its clinical and commercial progress at the Emerging Growth Conference 91 on April 2, 2026. The company will showcase JOTROL™, its patented resveratrol-based platform, which powers its therapeutic and consumer longevity products. Jupiter is developing treatments for CNS disorders and rare diseases while expanding its Nugevia™ product line for healthy aging. The presentation will be available...
03-31 16:00
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026 Jupiter Neurosciences Inc. (NASDAQ: JUNS) said it will participate in the BIO Investment and Growth Summit 2026, hosted by the Biotechnology Innovation Organization (BIO), on March 2–3, 2026 in Miami Beach, Florida, with its c
03-02 21:02
